TAMPA, Fla. - Oct 16, 2012 - - Creative Edge Nutrition, Inc (OTCBB: FIXT) has been a real mover the last two trading days. After trading 18 million shares Monday and climbing to .0138 FITX has pulled back today showing just over 6 million shares traded by midday and giving back the 30% gains seen at yesterday’s close. FIXT could be ripe for a bounce play. Keep it on you radar.
(PINKSHEETS: FITX) Creative Edge Nutrition, Inc. positions itself as a premier, value conscious diet supplement brand. Using leading edge technology, CENERGY (OTCBB: FITX brand) offers a line of customized products for both women and men fitness participants. The specific clients and users of the products are sports enthusiast, athletes, appealing to men 18 to 49, and our dietary products are targeted to women age 18 to 49. CENERGY will utilize strategic and tactical marketing through branding, labeling, promotions and endorsements by high profile celebrities and athletes. This unique exclusive marketing will be targeted to multiple demographics for sports nutrition and weight management products. FIXT will strive towards both domestic and international distribution and will utilize the same unique targeted marketing strategies.
For Awesome Penny Stock Picks Subscribe to http://www.Globalinvestmentalert.com/
(OTCBB: PWEI) PacWest Equities Inc. is suffering a major pullback today giving up over 50% of recent gains. Trading 16 million shares by 1:00 P.M. PWEI has dropped from an open at .66 to .31, down 53%
(OTCBB: PWEI) PacWest Equities Inc. specializes in working with underperforming companies and bringing together the resources needed for them to attain financial stability and growth. Our focus is on companies showing a positive upside while struggling to bring new technologies and unique products to market.
PacWest Equities Associates (OTCBB: PWEI) are an experienced team of accomplished and proven professionals. We provide results-driven solutions by leveraging investor relations, facilitating creative product development and fostering interactive services / partnerships. Our proven market strategies and operational dynamics specialize on new and emerging technologies and product development; this combined with our executive teams intrinsic ability to identify business opportunities and growth, is indeed the cornerstone of our success.
(OTCQB: GETH) Green EnviroTech Corp. announced that “the tire and plastic to oil samples that were approved in May 2012 precipitated the pricing at the "Brent Crude" spot price.” One oil company stated that lab result qualities of all GETH's oil samples were well within their specifications for their refinery.
In a press release CEO Gary De Laurentiis, stated, "This is very important step for GETH. It was necessary to the next phase of our planning to firmly establish the quality of what we are capable of producing. The result is 'Brent Crude' pricing that averages $18 per barrel higher than the NYMEX spot price. Our next step identifies the location of the first plant, apply for permits, and work with investment opportunities to fund the project. We are in the due diligence phase with several funding sources. Investors loved this exciting GETH news and the stock has traded 14 million shares and rocketed up 38% by midday. This may indicate longer trend for this green sector darling.
(OTCQB: GETH) Green EnviroTech Corp. is a large scale plastics recycling and recovery company which removes and cleans contaminants from recycled automotive vehicles to produce a compounded resin product. Its unique patented process significantly reduces the amount of shredder residue going to landfills by 40 percent, which creates considerable cost savings for metal recyclers and the environment. The company has developed strategic partnerships with metal recycling companies and plans to leverage its recovery and manufacturing processes to primarily focus on automotive and durable goods applications and the production of sweet crude oil. Green EnviroTech Corp is a wholly-owned subsidiary of Green EnviroTech Holdings Corp.
(OTCQB: CBIS) Cannabis Science, Inc. recently announced that its newly established CS-TATI-1 research program focuses on the development of CB1/CB2 agonists and antagonists for the treatment of AIDS-related Kaposi Sarcoma (KS). AIDS-related KS is the third leading cause of death of people living with HIV in Sub-Saharan Africa. Incidence of KS in the U.S. declined significantly after the initiation of HIV antiretroviral therapy in 1996; however, over the past several years a growing reemergence of KS in virally suppressed patients on HAART has indicated a need for new treatments for KS.
(OTCQB: CBIS) Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
"Cannabis Science™ works with World Authorities on phytocannabinoid science targeting critical illnesses. Adhering to scientific methodologies to develop, produce, and commercialize phytocannabinoid based pharmaceutical products."
Globalinvestmentalert.com offers a free newsletter featuring some of the best penny stock picks available. Our sole purpose is to find the best penny stock picks - period. To receive our awesome penny stock newsletter and alerts go to http://Globalinvestmentalert.com
Timing is everything when trading Penny Stocks. Be The First to Know by joining the GlobalInvestmentAlert.com newsletter. Our last four alerts have given our members over 1500% in gains.
For the Best Damn Stock Picks Subscribe to http://www.Globalinvestmentalert.com/
Disclosure: GlobalInvestmentAlert.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GlobalInvestmentAlert.com website, for complete risks and disclosures
Subscribe Here - http://www.Globalinvestmentalert.com/
Disclosure: Globalinvestmentalert.com/ is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment.
Please visit http://Globalinvestmentalert.com/ for complete risks and disclosures.
Contact: Globalinvestmentalert.com / mailto:firstname.lastname@example.org